Cardiac Mapping Market

Global Cardiac Mapping Market Size (2023 to 2028)

The global market size for cardiac mapping is estimated to grow to USD 769.05 million by 2028 from USD 494.5 million in 2023, growing at a CAGR of 9.23% from 2023 to 2028.

Cardia mapping is a technique for determining myocardial electric potential's temporal and unique distribution during a certain cardiac rhythm. Mapping specifically refers to elucidating the heart's operating system or comprehending the cardiac rhythm. Cardia mapping is a broad word that refers to various mapping techniques, including body surface, endocardial, and epicardial mapping.

Impact of COVID-19 on the global cardiac mapping market:

COVID-19 is a global public health crisis that has impacted virtually every firm. Its long-term consequences will impact the cardiac mapping market growth over the forecast period. The majority of healthcare, pharmaceutical, and biotechnology businesses have focused on diagnostics kits, safety gear (PPE kits, face shields, masks), and treatment therapies and drugs against the Novel coronavirus due to the COVID-19 outbreaks. In addition, R&D labs are working to develop an advanced vaccine against the Novel coronavirus. Furthermore, medical practitioners are busy providing COVID-19-related services, and experts to do cardiac mapping are unavailable. As a result, other areas of healthcare are being neglected. However, it has been discovered that the Novel coronavirus is prevalent among people suffering from illnesses such as arrhythmia. Therefore, diverse sources will make many investments and interventions in the medical industry. In addition, other chronic diseases will become a priority after COVID-19 cases drop. These factors suggest that the cardiac mapping market will continue to grow.

MARKET DRIVERS:

New entries into the market, increased investments, funding, and grants, rising incidence of target diseases, and an aging population are key factors driving the global cardiac mapping market forward.

The market for cardiac mapping is further expected to grow as technology improves, allowing for faster detection of complex arrhythmias and fewer diagnostic errors. These factors are likely to encourage physicians in hospitals to utilize technology to provide better treatment alternatives that are cost-effective for patients. As a result, these factors are likely to accelerate the market's growth rate. The global market for cardiac mapping is further expected to be growing due to an increase in the number of patients suffering from cardiac disorders such as coronary artery disease, hypertrophic cardiomyopathy, arrhythmia, myocardial infarction, and others. In addition, the availability of highly-qualified interventional cardiologists in developed economies and several innovative diagnostic technologies released by medical device firms are projected to enhance the growth of the cardiac mapping systems market over the forecast period.

Major market players have penetrated the healthcare industry to take advantage of the business opportunity, with technical developments assisting the growth of the cardiac mapping market in growing markets. Certain elements are assisting in the cardiac's prospective expansion. The subsequent developments in 3-D mapping technology will allow for creating a three-dimensional model of a heart chamber and the precise location of the placed catheter. This improves the resolution of cardiac activity maps and aids in accurately detecting aberrant diseases such as arrhythmia. In addition, artificial intelligence and robotics are being used to supplement medical practices worldwide, especially in industrialized countries. Following the epidemic, there will be a lot of intervention and investment in the medical and healthcare sectors. These factors suggest that the global cardiac mapping market will continue to expand.

MARKET RESTRAINTS:

During its growth period, the cardiac mapping market is exposed to restraints that can stifle market progress, such as undefined healthcare transformation and a scarcity of skilled people to manage electrophysiology. In addition, the expensive cost of these systems, their target specificity confined to a diagnosis of a few forms of arrhythmia, and a lack of understanding about cardiac mapping devices in underdeveloped countries are the challenges.

REPORT COVERAGE:

This research report on the global cardiac mapping market has been segmented and sub-segmented based on product, indication, end-user, and region.

Cardiac Mapping Market – By Product:

• Contact Cardiac mapping systems
  • Electro-anatomical mapping
  • Basket catheter mapping
  • Traditional endocardial catheter mapping
• Non-contact Cardiac mapping systems

The contact cardiac mapping systems segment is expected to develop at the fastest rate during the forecast period. Contact cardiac mapping's advantages, such as detecting the precise locations of mapping and ablation catheters in a three-dimensional environment and multi-electrode basket catheters, where recording just a few beats may be enough to uncover the arrhythmia circuit, are driving its adoption. As a result, there is an increasing demand for cardiac mapping equipment for diagnosing complex arrhythmias.

Cardiac Mapping Market – By Indication:

• Atrial Fibrillation
• Atrial Flutter
• AVNRT
• Other Arrhythmias

In the indication segment of the worldwide cardiac mapping market, atrial fibrillation had the most significant share of the global cardiac mapping market in 2022. Atrial fibrillation is a word for irregular and rapid heart rate that causes an increase in heart rate and heart-related issues. The main issue with atrial fibrillation is the risk of blood clots forming in the heart's upper chamber. These clots can spread to other organs in the body, causing obstruction and severe heart attacks or death. Atrial fibrillations are a prominent indicator of heart disease, and they can be avoided for a specific length of time. Furthermore, rising obesity, irregular exercise, bad diets, and lifestyle patterns contribute to the rise of atrial fibrillation.

Cardiac Mapping Market – By End-User:

• Hospitals
• Clinics
• Diagnostic and Imaging Centers

The hospital segment is expected to dominate the market among all the other segments based on end-user. The dominance of the hospitals segment in the global cardiac mapping systems market in share was due to increased investment by public and private players in multispecialty hospitals to improve healthcare infrastructure and an increase in the adoption of advanced and precise diagnostic tools by interventional cardiologists in hospitals.

Cardiac Mapping Market – By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Geographically, North America dominated the cardiac mapping market and is expected to continue throughout the forecast period. The North American cardiac mapping market is being driven by factors such as an increase in the approval rate of mapping systems and clinical trials validating cardiac mapping systems in the United States, a high incidence of CVDs, a growing focus of government organizations on providing funding for research, and an increasing geriatric population in Canada.

Over the forecast period, Asia-Pacific is expected to have the most significant CAGR. Factors such as a larger patient pool for CVDs, rising demand for advanced systems, and better healthcare infrastructure will contribute to the Cardiac Mapping market's lucrative growth prospects in the Asia-Pacific region.

KEY MARKET PLAYERS:

Abbott, Acutus Medical, Biosense Webster, BIOTRONIK, Boston Scientific Corporation, EP Solutions SA, Koninklijke Philips N.V., Lepu Medical, Medtronic, and MicroPort Scientific Corporation are some of the promising companies operating in the global cardiac mapping market profiled in this report.

RECENT HAPPENINGS IN THIS MARKET:

• In 2019, Acutus Medical announced to expand of its AFib offerings, as well as a strategic acquisition and new monitoring and therapy partnerships.
• The TactiCath Contact Force Ablation Catheter, Sensor Enabled, was approved by the US Food and Drug Administration (FDA) in 2019. It is a new ablation catheter meant to help clinicians precisely and successfully treat atrial fibrillation (AFib).